BARD1 Life Sciences Limited

Short Term Long Term Short Term Comparison Long Term Comparison
  • BD1
  • 1d-1.42%
  • 1w4.00%
  • 1m-11.86%
  • 1y-39.53%
ATH
  • ATH Price$421.83
  • ATH Date1988-04-29
  • % since ATH-99.75%
  • % to ATH40,460.10%
ATL
  • ATL Price$0.17
  • ATL Date2017-12-20
  • % from ATL495.65%
  • Last Low Price$0.1746
  • Last Low Date2017-12-20
  • % From Last Low495.65%
IPO
  • IPO Price$236.22
  • % Current ROI USD-99.56%
  • ATH Price$421.83
  • % ROI ATH 24,159,507.45%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="BD1"]

Key Data [addtoany]

Current price $1.04
Sector Healthcare
Industry Diagnostics & Research
Today's High/Low $1.05/$1.03
Volume 38,859.00
Previous Close $1.055
52 Week High/Low $5.6/$0.95
Market Cap 95,239,352.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $0
Annualized Dividend $0
$1.04
[addtoany]

BARD1 Life Sciences Limited engages in the research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer to enhance patient outcomes and save lives in Australia.
Its cancer diagnostics portfolio includes commercialized hTERT test used as an adjunct to urine cytology testing; and diagnostic tests in development for ovarian, breast, lung, prostate, and pancreatic cancers.
The company is also providing Molecular NET technology, including its EXO-NETTM product to capture and purify exosomes.
BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in Notting Hill, Australia.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity